慢性乙型肝炎患者体内不同来源标本中miR-146a和miR-155的表达

目的：通过检测慢性乙型肝炎(chronic hepatitis B，CHB)患者不同来源标本中miR-146a和miR-155的表达，了解不同来源标本中2种miRNAs表达的相关性，为研究miRNA在肝病中的作用机制提供标本选择的理论依据。方法：采用real-time PCR对41例CHB患者核苷(酸)类似物抗病毒治疗基线期和第104周血浆、外周血单个核细胞和肝组织中miR-146a和miR-155的表达进行检测，分析3种来源标本中这2种miRNAs表达的相关性。结果：治疗第104周时血浆、外周血单个核细胞和肝组织miR-146a和miR-155的表达水平均较基线期显著下调(P<0.05)。基线期血浆和肝组织(r=0.560，P=0.007)、外周血单个核细胞和肝组织(r=0.428，P=0.047)miR-146a的表达均相关。基线期血浆和肝组织(r=0.587，P=0.004)、外周血单个核细胞和肝组织(r=0.483，P=0.023)miR-155的表达相关，miR-146a和miR-155在血浆中的表达与外周血单个核细胞中的表达不相关(P>0.05)。结论：与外周血单个核细胞相比，血浆中miR-146a和miR-155的表达能更好地反映和预测肝组织miR-146a和miR-155的表达，血浆可作为研究miR-146a和miR-155在肝病中作用机制的标本来源。

Expressions of miR-146a and miR-155 in different samples of chronic hepatitis B patients

Objective: To detect the levels of miR-146a and miR-155 in different samples from chronichepatitis B (CHB), reveal whether there is a correlation between the 2 miRNAs in differentsamples, and to provide a theoretical basis for sample choice of miRNA research in liver.Methods: Real-time PCR was conducted to examine the expression of miR-146a and miR-155 inthe plasma, peripheral blood mononuclear cell (PBMC), and liver tissues from 41 CHB patientswho underwent nucleoside analogues antiviral therapy for 104 weeks. Correlations between thelevels of miR-146a and miR-155 among the 3 samples were analyzed.Results: The expressions of miR-146a and miR-155 in the plasma, PBMC and liver tissues weresignificantly down-regulated at the 104th week than those at the baseline (all P<0.05). There wasa correlation in the expression of miR-146a between plasma and liver tissues (r=0.560, P=0.007),PBMC and liver tissues (r=0.428, P=0.047) at baseline. There was a correlation in the expressionof miR-155 between plasma and liver tissue (r=0.587, P=0.004), PBMC and liver tissue (r=0.483,P=0.023) at baseline. The expressions of miR-146a and miR-155 between the plasma and PBMCwere not correlated (P>0.05).Conclusion: Compared with PBMC, miR-146a and miR-155 from plasma can better reflect theexpression in the liver tissues, suggesting that plasma can be applied in the mechanism research onmiR-146a and miR-155 in the liver diseases instead of liver tissues.